{"id":508657,"date":"2021-07-01T06:48:08","date_gmt":"2021-07-01T10:48:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"},"modified":"2021-07-01T06:48:08","modified_gmt":"2021-07-01T10:48:08","slug":"ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","title":{"rendered":"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease<\/b><\/p>\n<p>LAS VEGAS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aultglobal.com%2F&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=Ault+Global+Holdings%2C+Inc.&amp;index=1&amp;md5=14e76e96feaca24a742fb9caa706769d\">Ault Global Holdings, Inc.<\/a> (NYSE American: DPW) a diversified holding company (the \u201c<b>Company<\/b>\u201d), announced today that <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Alzamend.com&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=Alzamend+Neuro%2C+Inc.&amp;index=2&amp;md5=d2415980d40026f31c3a15ff10047510\">Alzamend Neuro, Inc.<\/a> (Nasdaq: ALZN) (\u201c<b>Alzamend<\/b>\u201d), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, submitted an investigational new drug (\u201c<b>IND<\/b>\u201d) application to the FDA for the initiation of a Phase 1 clinical study of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alzamend.com%2Fpipeline%2F&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=AL001&amp;index=3&amp;md5=9e8ee0e219be4ec2567b3aa072552c39\">AL001<\/a> on June 30, 2021. The Phase 1, first-in-human study, is designed for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer\u2019s disease.\n<\/p>\n<p>\nFollowing completion of this initial study, Alzamend intends to initiate a Phase 1\/2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AL001 in Alzheimer\u2019s disease patients. Presuming favorable data, a subsequent Phase 2b program is planned to target appropriate doses for the pivotal Phase 3 safety\/efficacy clinical program required for regulatory approval.\n<\/p>\n<p>\n\u201cThis IND submission represents a key milestone for Alzamend as we continue to advance our proprietary pipeline. We believe AL001 could potentially provide clinicians with a major improvement over current lithium-based treatments and may constitute a means of treating Alzheimer\u2019s disease and other neurodegenerative diseases and psychiatric disorders. We look forward to providing more details on the timeline and market opportunity following FDA clearance of the IND, if obtained,\u201d commented Stephan Jackman, Chief Executive Officer of Alzamend.\n<\/p>\n<p>\nBased on preclinical data, AL001 treatment prevents cognitive deficits, depression, and irritability in APPSWE\/PS1dE9 mice, and has shown an improvement of associative learning and memory and irritability compared with lithium carbonate treatments, supporting the potential of this lithium formulation for the treatment of Alzheimer\u2019s disease and psychiatric disorders. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially allowing Alzamend to rely upon this existing data, potentially reducing the regulatory burden for safety data.\n<\/p>\n<p>\nAlzamend\u2019s mission is to help the Alzheimer\u2019s disease community by supporting the full product development life cycle of treatment and cures for dementia and Alzheimer\u2019s disease driven by the belief that strong support of research is the foundation for true innovation. Dementia is not a normal part of aging, and there are numerous symptoms that can indicate cognitive and neurological impairments. Alzheimer\u2019s disease is the most common form of dementia. This disease robs people of their loved ones, as memories are erased and personalities are diminished. Alzamend\u2019s vision statement nicely sums up their mission: \u201c<b><i>Together We Can \u2018Make Alzheimer\u2019s Just a Memory!<\/i><\/b>\u2019\u2122\u201d.\n<\/p>\n<p>\nThe economic impact of Alzheimer\u2019s disease can be as devastating as the emotional stress. Over 47 million people in the world currently live with Alzheimer\u2019s disease or dementia, with over 6.2 million in the U.S. (two-thirds are women). The lifetime cost of care for an Alzheimer\u2019s disease patient is estimated at $374,000 in the U.S. According to the Alzheimer\u2019s Association, it is estimated that Alzheimer\u2019s and dementia deaths increased more than 16% in 2021 due to COVID-19. In 2021, Alzheimer\u2019s and dementia will cost the U.S. an estimated $355 billion with the costs expected to rise into the trillions in the next 25 years. In, addition, Medicare and Medicaid is expected to pay approximately $239 billion, or 67% of the treatment and long-term care costs associated with Alzheimer\u2019s disease and dementia, with another $79 billion of out-of-pocket costs. According to the Alzheimer\u2019s Association, eleven million Americans provide an estimated 15.3 billion hours of unpaid care per year, valued at $257 billion, for these patients with two-thirds of these being women, and one-third being daughters.\n<\/p>\n<p>\nMilton \u201cTodd\u201d Ault, III, the Company\u2019s Executive Chairman, stated, \u201cThe Company is pleased that Alzamend has achieved this milestone to further its commitment to develop treatments and cures for Alzheimer\u2019s, other neurodegenerative diseases and psychiatric disorders.\u201d\n<\/p>\n<p>\nThe Company has certain beneficial ownership and rights to further invest in Alzamend as follows:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Company beneficially owns approximately 5.3 million shares of Alzamend common stock held by its wholly owned subsidiary, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.digitalpowerlending.com&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=Digital+Power+Lending%2C+LLC&amp;index=4&amp;md5=1efda42c12085f5e9371889ce531ef71\">Digital Power Lending, LLC<\/a> (\u201c<b>DPL<\/b>\u201d).\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nThe Company has the right to acquire 1.35 million shares of Alzamend common stock upon the exercise of warrants beneficially owned by DPL.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nIn March 2021, Alzamend entered into a securities purchase agreement with DPL pursuant to which Alzamend agreed to sell an aggregate of 6.7 million shares of its common stock for an aggregate of $10 million, or $1.50 per share, which sales will be made in tranches. Alzamend further agreed to issue to DPL warrants to purchase such number of shares of its common stock equal to 50% of the shares of common stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. On March 9, 2021, the Company purchased 2.7 million shares of Alzamend common stock (included in the 5.3 million shares of Alzamend common stock held by DPL described above) upon closing of the first tranche of $4 million. Under the terms of the securities purchase agreement, DPL may purchase an additional 4.0 million shares.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nFinally, Alzamend agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million.\n<\/li>\n<\/ul>\n<p>\nShould the Company exercise all warrants and options to invest, it would own approximately 22.6 million shares with an average cost of $2.27 per share of common stock, representing 22% of Alzamend\u2019s issued and outstanding common stock.\n<\/p>\n<p>\nFor more information on Ault Global Holdings and its subsidiaries, the Company recommends that stockholders, investors and any other interested parties read the Company\u2019s public filings with the SEC, available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=80120130b93614e9f26363a5d104203d\">www.sec.gov<\/a>, and press releases available under the Investor Relations section at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.AultGlobal.com&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=www.AultGlobal.com&amp;index=6&amp;md5=5eb6f96c5e0b24b817df7e16c5ff08c6\">www.AultGlobal.com<\/a>.\n<\/p>\n<p><b>About Ault Global Holdings, Inc.<\/b><\/p>\n<p>\nAult Global Holdings, Inc. is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Through its wholly and majority-owned subsidiaries and strategic investments, the Company provides mission-critical products that support a diverse range of industries, including defense\/aerospace, industrial, automotive, telecommunications, medical\/biopharma, and textiles. In addition, the Company extends credit to select entrepreneurial businesses through a licensed lending subsidiary. Ault Global Holdings\u2019 headquarters are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141; <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.AultGlobal.com&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=www.AultGlobal.com&amp;index=7&amp;md5=dd61c7983256cb901c36c8aa108c480d\">www.AultGlobal.com<\/a>.\n<\/p>\n<p><b>About Alzamend Neuro<\/b><\/p>\n<p>\nAlzamend Neuro, Inc. (\u201cAlzamend\u201d) (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Alzamend.com&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=www.Alzamend.com&amp;index=8&amp;md5=6c94c9325b4fa2ca51bffbb8219a07cc\">www.Alzamend.com<\/a>), is a Delaware corporation with its corporate headquarters in Tampa, Florida. The mission of Alzamend is to help the Alzheimer\u2019s community by supporting the full product development life cycle of treatment and cures of neurodegenerative diseases and psychiatric disorders, including Alzheimer\u2019s disease. With Alzamend\u2019s two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Alzamend\u2019s current pipeline consists of two novel therapeutic drug candidates, AL001 &#8211; a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate, and AL002 &#8211; a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient\u2019s immunological system to combat Alzheimer\u2019s disease. Both of Alzamend\u2019s product candidates are licensed from the pursuant to royalty-bearing exclusive worldwide licenses from the University of South Florida. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Alzamend.com&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=www.Alzamend.com&amp;index=9&amp;md5=37d606a6d633aa740e5ddc7366d93172\">www.Alzamend.com<\/a><\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains \u201cforward looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cpotential,\u201d or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company\u2019s business and financial results are included in the Company\u2019s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company\u2019s Forms 10-K, 10-Q and 8-K. All filings are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=87ae1d5b720d2c3abeb09ab95a0985dc\">www.sec.gov<\/a> and on the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.AultGlobal.com&amp;esheet=52454161&amp;newsitemid=20210701005418&amp;lan=en-US&amp;anchor=www.AultGlobal.com&amp;index=11&amp;md5=49e376df227d31f1d7d8059f4a1ba55b\">www.AultGlobal.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210701005418\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210701005418\/en\/<\/a><\/span><\/p>\n<p><a rel=\"nofollow\" href=\"mailto:IR@AultGlobal.com\">IR@AultGlobal.com<\/a> or 1-888-753-2235\n<\/p>\n<p><b>KEYWORDS:<\/b> Nevada United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Other Manufacturing Technology FDA Other Technology Clinical Trials Manufacturing Biotechnology General Health Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210701005418\/en\/1027309\/3\/Ault_Global_Holdings_Corporate_Logo_01192021.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease LAS VEGAS&#8211;(BUSINESS WIRE)&#8211;Ault Global Holdings, Inc. (NYSE American: DPW) a diversified holding company (the \u201cCompany\u201d), announced today that Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, submitted an investigational new drug (\u201cIND\u201d) application to the FDA for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study, is designed for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-508657","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease LAS VEGAS&#8211;(BUSINESS WIRE)&#8211;Ault Global Holdings, Inc. (NYSE American: DPW) a diversified holding company (the \u201cCompany\u201d), announced today that Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, submitted an investigational new drug (\u201cIND\u201d) application to the FDA for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study, is designed for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients &hellip; Continue reading &quot;Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T10:48:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease\",\"datePublished\":\"2021-07-01T10:48:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\"},\"wordCount\":1528,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\",\"name\":\"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-01T10:48:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk","og_description":"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease LAS VEGAS&#8211;(BUSINESS WIRE)&#8211;Ault Global Holdings, Inc. (NYSE American: DPW) a diversified holding company (the \u201cCompany\u201d), announced today that Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, submitted an investigational new drug (\u201cIND\u201d) application to the FDA for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study, is designed for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients &hellip; Continue reading \"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T10:48:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease","datePublished":"2021-07-01T10:48:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"},"wordCount":1528,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","name":"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-01T10:48:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005418r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ault-global-holdings-announces-that-alzamend-neuro-has-submitted-an-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=508657"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=508657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=508657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=508657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}